Ruthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB1 Receptor Imaging Agent [18F]FPATPP

Tietueen suppeat tiedot
dc.contributor.authorLahdenpohja S
dc.contributor.authorRajala N
dc.contributor.authorHelin JS
dc.contributor.authorHaaparanta-Solin M
dc.contributor.authorSolin O
dc.contributor.authorLópez-Picón FR
dc.contributor.authorKirjavainen A
dc.contributor.organizationfi=MediCity|en=MediCity|
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=kemian laitos|en=Department of Chemistry|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.14646305228
dc.contributor.organization-code1.2.246.10.2458963.20.27622076134
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id48476573
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/48476573
dc.date.accessioned2022-10-28T12:42:37Z
dc.date.available2022-10-28T12:42:37Z
dc.description.abstract<p>Cannabinoid receptor 1 (CB1R) controls various physiological and pathological conditions, including memory, motivation, and inflammation, and is thus an interesting target for positron emission tomography (PET). Herein, we report a ruthenium-mediated radiolabeling synthesis and preclinical evaluation of a new CB1R specific radiotracer, [18F]FPATPP. [18F]FPATPP was produced with 16.7 ± 5.7% decay-corrected radiochemical yield and >95 GBq/μmol molar activity. The tracer showed high stability, low defluorination, and high specific binding to CB1Rs in mouse brain.<br /></p>
dc.format.pagerange2009
dc.format.pagerange2018
dc.identifier.eissn1948-7193
dc.identifier.jour-issn1948-7193
dc.identifier.olddbid178400
dc.identifier.oldhandle10024/161494
dc.identifier.urihttps://www.utupub.fi/handle/11111/35911
dc.identifier.urnURN:NBN:fi-fe2021042826183
dc.language.isoen
dc.okm.affiliatedauthorLahdenpohja, Salla
dc.okm.affiliatedauthorRajala, Noora
dc.okm.affiliatedauthorHelin, Jatta
dc.okm.affiliatedauthorHaaparanta-Solin, Merja
dc.okm.affiliatedauthorDataimport, MediCity
dc.okm.affiliatedauthorSolin, Olof
dc.okm.affiliatedauthorLopez Picon, Francisco
dc.okm.affiliatedauthorKirjavainen, Anna
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3112 Neurosciencesen_GB
dc.okm.discipline3112 Neurotieteetfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherACS Publisher
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1021/acschemneuro.0c00313
dc.relation.ispartofjournalACS Chemical Neuroscience
dc.relation.issue13
dc.relation.volume11
dc.source.identifierhttps://www.utupub.fi/handle/10024/161494
dc.titleRuthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB1 Receptor Imaging Agent [18F]FPATPP
dc.year.issued2020

Tiedostot

Näytetään 1 - 1 / 1
Name:
Lahdenpohja_et_al_acschemneuro.0c00313.pdf
Size:
3.51 MB
Format:
Adobe Portable Document Format
Lataa

Kokoelmat

Rinnakkaistallenteet